There is a vast amount of anti-aging hype out there. Some of this involves stem cell-related approaches. In posts in this category Professor Paul Knoepfler fact-checks the hype, focusing on data.
At the beginning of the year I wrote about a new kind of biotech called Altos Labs. It’s very different in some ways from other institutions. I find it an intriguing research entity. Where do things stand now with Altos Labs a few months later? More information, new ideas, and questions have popped up in the […]
Altos Labs: mission, leadership, jobs, & CIRM Read More »
When we hear the word senile we might think stereotypically of an older person who has cognitive impairment, but some argue that senility can apply to cells too as they age and that such cells can be targeted by drugs called senolytics. Unfortunately, the supplements industry has picked up on this idea to sell iffy
Recommended reads: senolytics, cow iPS cells, big CIRM royalty Read More »
The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
I wrote briefly a few months ago about Altos Labs. It’s a new kind of biotech institute that is focused on cellular reprogramming. Now we know much more and it’s clear this is a huge deal. What’s in this article What is Altos Labs? | Cellular rejuvenation | Reprogramming oldness | Challenges | Altos Strategies | Analysis of
All about Altos Labs and $3B cellular rejuvenation push Read More »
This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant
Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »
Stem cells may have anti-aging properties, but they are unlikely to be a real fountain of youth. Even so, people are obsessed with aging and stem cells regularly are thought of as “the ticket” for fighting aging. I’ll start today’s recommended reads with that topic and then go on to list some interesting papers of
Weekly reads: Bezos & stem cells for anti-aging, Myc, more Read More »
My weekly roundups of biomedical news tend to focus on stem cells, but I read more broadly so it’s not just stem cells but also CAR-T cells and a lot more this week. CAR-T cells as senolytics? A team led by Scott Lowe has a new intriguing paper in Nature on using CAR-T cells to
Weekly roundup: CAR-T cells, exosomes, trout cloning Read More »
Remember our old friends Liveyon? Their leader John Kosolcharoen? Liveyon’s continuing metamorphosis This biologics supply firm has gone through several stages of corporate metamorphosis as a supplier of biologics including at first a purported living umbilical cord stem cell product. That stem cell thrust ultimately landed a dozen or more people in the hospital as
Liveyon is back (again) with unproven exosome product Read More »
Gwyneth Paltrow has a new Netflix show coming up in a couple of weeks called “The Goop Lab” and her Goop company promotes a lot of wacky things so one Sunday over lunch I thought I’d take a look at what they sell related to stem cells. Going into this, I didn’t know for sure
As Goop Lab TV show approaches, my look at their ‘stem cell’ products Read More »
A fitness guru named Ben Greenfield has now reported self-injecting non-FDA approved stem cells from US Stem Cell. He says the stem cells came from a clinic that lost a big federal court case 9 days ago. Greenfield posted a Facebook video of the actual injection, which he narrates. There’s some text along with the
Ben Greenfield DIY injection of risky stem cells Read More »